William Freeman is an Ophthalmology physician affiliated with Fleet Science Center. OpenAlex indexes 229 publications with 6,185 citations (h-index 44); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039000
Telephone
858-534-6290Registry record last updated 23 Apr 2018.
Clinical trials
- Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
Sponsor: Mayo Clinic
- Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20251 payment
- Ellex, IncProgram year20242 payments
- Harrow Eye, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
96.1%Antineovascularisation agents95.7%Faricimab-svoa100%Part B, office-administered≥37 patientsCarbonic Anhydrase Inhibitor0.2%Dorzolamide-Timolol100%Part D≥21 patients+ 2 more classes in this area
Cancer & immunology
3.7%Vascular Endothelial Growth Factor Inhibitor3.7%Aflibercept96%Bevacizumab4%Part B, office-administered≥60 patientsMusculoskeletal
0.1%Cyclooxygenase Inhibitor0.1%Ketorolac Tromethamine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 1988–2026 per NIH RePORTER. The latest:
- Intracellular RNA Nanoparticle Therapeutics to Treat Retinal Neovascularization
University of California, San Diego
FY2026$413,374R01EY035262 - Intracellular RNA Nanoparticle Therapeutics to Treat Retinal Neovascularization
University of California, San Diego
FY2025$413,374R01EY035262 - Intracellular RNA Nanoparticle Therapeutics to Treat Retinal Neovascularization
University of California, San Diego
FY2024$413,374R01EY035262
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Towards high-resolution retinal prostheses with direct optical addressing and inductive telemetry
Journal of Neural Engineering
2016 - Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial
American Journal of Ophthalmology
2015
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”